A Phase 2 interventional study of ATI-50002 in Androgenetic Alopecia, sponsored by Aclaris Therapeutics, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-12-09.
Sponsored by Aclaris Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Alopecia with a site in United States — 44 open to participants now, 64 under way, 6 of them phase 3. Alopecia · United States.
Among the 217 studies in Alopecia with a site in United States, this one is the 126th largest by enrollment of the 204 interventional ones that give a count, is one of 13 that started in 2018, is one of 48 in phase 2, and was the 86th registered.
512 studies on the registry are indexed under Alopecia; 128 are open to participants now.
Browse Alopecia studies →44 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States
Ages 18–65 · Women only
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 58 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 13 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 204 interventional studies, 204 across the 12 observational. Of the 126 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 217 have an industry lead sponsor. The 10 most frequent:
Aclaris Therapeutics, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 22 (88%) have results posted.
Aclaris Therapeutics, Inc. has 2 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
29 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 217 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
This is an open-label study designed to evaluate the safety and efficacy of ATI-50002 Topical Solution in male and female subjects with androgenetic alopecia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a clinical diagnosis of androgenetic alopecia.
Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length on their balding spot.
Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the center of the identified target area.
Subjects must agree to maintain the same hair style and hair care regimen during the study.
Exclusion Criteria:
Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.
Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss on the treatment area, due to disease, injury or medical therapy.
Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments or efficacy or safety.
This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia. Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks.
Drug: ATI-50002
ATI-50002 Topical Solution
Mean Change From Baseline in Target Area Hair Count (TAHC)
Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.
Time frame: Baseline to 26 Weeks
Mean Change From Baseline in Target Area Hair Count (TAHC)
Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.
Time frame: Baseline to 52 Weeks
Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)
Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.
Time frame: Baseline to 26 Weeks
Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)
Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.
Time frame: Baseline to 52 Weeks
Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale
Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
Time frame: Baseline to 26 Weeks
Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale
Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
Time frame: Baseline to 52 Weeks
Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale
Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
Time frame: Baseline to 26 Weeks
Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale
Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
Time frame: Baseline to 52 Weeks
Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale
Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects. Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.
Time frame: Baseline to 26 Weeks
Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale
Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects. Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.
Time frame: Baseline to 52 Weeks
Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale
Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women. Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over. Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part. Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp. Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.
Time frame: Baseline to 26 Weeks
Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale
Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women. Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over. Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part. Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp. Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.
Time frame: Baseline to 52 Weeks
| Milestone | ATI-50002 Topical Solution |
|---|---|
| Started | 31 |
| Completed | 23 |
| Not completed | 8 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Lost to follow-up | 1 |
| Milestone | ATI-50002 Topical Solution |
|---|---|
| Started | 19 |
| Completed | 17 |
| Not completed | 2 |
| Withdrew: Lost to follow-up | 2 |
Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.
| hairs/cm^2 | ATI-50002 Topical Solution |
|---|---|
| Mean Change From Baseline in Target Area Hair Count (TAHC) | 8.6 ± 12.87 |
Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.
| hairs/cm^2 | ATI-50002 Topical Solution |
|---|---|
| Mean Change From Baseline in Target Area Hair Count (TAHC) | 1.6 ± 18.92 |
Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.
| microns | ATI-50002 Topical Solution |
|---|---|
| Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW) | 403.69 ± 817.271 |
Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.
| microns | ATI-50002 Topical Solution |
|---|---|
| Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW) | 35.28 ± 901.082 |
Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
| Participants | ATI-50002 Topical Solution |
|---|---|
| Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale | 16 |
Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
| Participants | ATI-50002 Topical Solution |
|---|---|
| Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale | 8 |
Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
| Participants | ATI-50002 Topical Solution |
|---|---|
| Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale | 18 |
Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
| Participants | ATI-50002 Topical Solution |
|---|---|
| Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale | 13 |
Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects. Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.
| Participants | ATI-50002 Topical Solution |
|---|---|
| Improvement from Type V to Type III Vertex | 2 |
| Improvement from Type V to Type IV | 1 |
| Improvement from Type IV to Type III Vertex | 1 |
| Improvement from Type III to Type III Vertex | 2 |
| No Improvement Measured | 9 |
Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects. Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.
| Participants | ATI-50002 Topical Solution |
|---|---|
| Improvement from Type V to Type III Vertex | 1 |
| Improvement from Type III Vertex to Type II | 1 |
| Improvement from Type V to Type IV | 1 |
| Improvement from Type IV to Type III Vertex | 1 |
| Improvement from Type III Vertex to Type III | 1 |
| No Improvement | 9 |
Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women. Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over. Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part. Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp. Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.
| Participants | ATI-50002 Topical Solution |
|---|---|
| Improvement from Grade 4 to Grade 3 | 1 |
| Improvement from Grade 2 to Grade 1 | 1 |
| No Measured Improvement | 5 |
Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women. Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over. Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part. Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp. Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.
| Participants | ATI-50002 Topical Solution |
|---|---|
| Improvement from Grade 4 to Grade 3 | 1 |
| Improvement from Grade 3 to Grade 2 | 1 |
| No Improvement | 1 |
Collected over Open Label = 26 weeks; Extension period = 26 weeks; Reporting of non-serious AEs started with each subject's first study medication application and continued until 30 days following the last application of study medication. Events with onset dates more than 30 days after the last application of study medication were considered as "post-therapy.". Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATI-50002 Topical Solution | 0/31 (0%) | 1/31 (3.2%) | 18/31 (58.1%) |
| Event | ATI-50002 Topical Solution |
|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/31 |
| Event | ATI-50002 Topical Solution |
|---|---|
| VertigoEar and labyrinth disorders | 2/31 |
| Upper respiratory tract infectionInfections and infestations | 2/31 |
| Neck painMusculoskeletal and connective tissue disorders | 2/31 |
| AlopeciaSkin and subcutaneous tissue disorders | 2/31 |
| PhotopsiaEye disorders | 1/31 |
| ConstipationGastrointestinal disorders | 1/31 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 1/31 |
| Chest painGeneral disorders | 1/31 |
| FolliculitisInfections and infestations | 1/31 |
| InfluenzaInfections and infestations | 1/31 |
| Age, Continuous(years) | ATI-50002 Topical Solution |
|---|---|
| Mean | 38.2 ± 6.49 |
| Sex: Female, Male(Participants) | ATI-50002 Topical Solution |
|---|---|
| Female | 10 |
| Male | 21 |
| Ethnicity (NIH/OMB)(Participants) | ATI-50002 Topical Solution |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | ATI-50002 Topical Solution |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 1 |
| White | 25 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | ATI-50002 Topical Solution |
|---|---|
| United States | 31 |
| Height(centimeters) | ATI-50002 Topical Solution |
|---|---|
| Mean | 173.7 ± 9.04 |
| Weight(kilograms) | ATI-50002 Topical Solution |
|---|---|
| Mean | 89.4 ± 20.74 |
| Fitzpatrick Skin Type(Participants) | ATI-50002 Topical Solution |
|---|---|
| I - Always Burns | 3 |
| II - Burns Easily | 11 |
| III - Burns Moderately | 10 |
| IV - Burns Minimally | 4 |
| V - Rarely Burns | 2 |
| VI - Never Burns | 1 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Oct 2019, 18 months.
Results were first posted in Dec 2020, 1 year 1 month after primary completion.
Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 18 months is above that.
Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ifidancitinib